Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LSTA with free AI briefings, catalyst countdowns, and dilution alerts.

LSTA · LISATA THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$19.3M Cash on Hand
20.2mo Cash Runway
Follow LSTA by email Get an email when LSTA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LSTA, unsubscribe in one click. Privacy

📣 What LSTA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Eltrapuldencel-T Stage IV Melanoma Phase 3 · NCT01875653 Terminated
Cell Chronic Myocardial Ischemia Phase 3 · NCT01508910 Completed
Therapeutic Autologous Dendritic Cells Melanoma (Skin) Phase 1/2 · NCT00012064 Completed
SOC Critical Limb Ischemia Phase 2 · NCT02501018 Completed
Carmustine Implant Brain and Central Nervous System Tumors Phase 2 · NCT00814593 Withdrawn
Autologous Bone Marrow-derived… ST Segment Elevation Myocardial Infarction Phase 2 · NCT01495364 Completed
Nab-paclitaxel Pancreas Cancer Phase 1/2 · NCT06592664 Withdrawn
Lymphokine-Activated Killer Cells Brain and Central Nervous System Tumors Phase 2 · NCT00814593 Withdrawn
CLBS16 Coronary Microvascular Dysfunction Phase 2 · NCT04614467 Terminated
Hematopoietic Progenitor Cell Antigen CD34 Critical Limb Ischemia Phase 2 · NCT02501018 Completed
CLBS03 High Dose Diabetes Mellitus Phase 2 · NCT02691247 Completed
Certepetide Cholangiocarcinoma Phase 2 · NCT05712356 Completed
CLBS201 Chronic Kidney Diseases Phase 1 · NCT04990427 Completed
CLBS119 Covid-19 Phase 1 · NCT04522817 Withdrawn
Internalized-arginylglycylaspartic Acid Cyclic… Pancreatic Cancer Phase 1 · NCT03517176 Completed
Biological Challenge Agent Kidney Cancer Phase 1 · NCT00014131 Terminated

Also used in these trials (approved or third-party drugs, not LSTA's own candidates): Autologous PBMCs in GM-CSF, Gemcitabine Hydrochloride, Oxaliplatin, Durvalumab, Cisplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LSTA holds $19.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 20.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LSTA files for a raise →

👥 Who Owns LSTA

Insiders 9.2% Other 5%+ holders 4.3% Institutions (38 holders) 13.8% Public and other holders 72.7%
HolderTypeShares% of sharesAs of
Branham Justin Earl 5%+ holder (13G) 462,149 4.28% 2026-08-21
David J Mazzo
President & CEO, Director · +127,000 options
Insider 311,890 2.89% 2026-01-09
Mohammad Azab
Director
Insider 104,925 0.97% 2026-01-09
Steven M Klosk
Director
Insider 95,815 0.89% 2026-01-09
Gregory B Brown
Director
Insider 95,659 0.89% 2026-01-09
Cynthia Louise Flowers
Director
Insider 95,446 0.88% 2026-01-09
Kristen K Buck
EVP, R&D and CMO · +40,000 options
Insider 93,462 0.87% 2026-01-09
Heidi Henson
Director
Insider 85,725 0.79% 2026-01-09
Tariq Imam
SVP, Bus Dev, General Counsel · +7,000 options
Insider 36,078 0.33% 2026-01-09
James Nisco
SVP, Fin/Treas, Chief Actg Off · +14,000 options
Insider 32,311 0.30% 2026-01-09
Joshua Lehrer-Graiwer
President & COO
Insider 27,808 0.26% 2026-09-17
Ted W Love
Director
Insider 19,260 0.18% 2026-09-17

Share count 10,804,066 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LSTA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LSTA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.